[1]赵晋华.18F-FDG PET在淋巴瘤分期和治疗反应评价中的价值[J].国际放射医学核医学杂志,2004,28(5):210-212.
　ZHAO Jin-hua.18F-FDG PET in the staging and evaluating of the response to therapy for lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(5):210-212.
点击复制

18F-FDG PET在淋巴瘤分期和治疗反应评价中的价值(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
28
期数:
2004年第5期
页码:
210-212
栏目:
核医学
出版日期:
1900-01-01

文章信息/Info

Title:
18F-FDG PET in the staging and evaluating of the response to therapy for lymphoma
作者:
赵晋华
200080 上海, 上海交通大学附属第一人民医院核医学科
Author(s):
ZHAO Jin-hua
Department of Nuclear Medicine, The First People’s Hospital Affiliated to Shanghai Jiaotong University, Shanghai 200080, China
关键词:
淋巴瘤; 肿瘤分期; 治疗反应; 正电子发射体层显像; 18F-氟代脱氧葡萄糖
Keywords:
lymphoma; stage; response to therapy; positron emission tomography; 18F-fluorodeoxyglucose
分类号:
R817.4
摘要:
18F-FDG PET显像对淋巴瘤的诊断、分期作用显著,对淋巴瘤病灶的探测灵敏度和准确性高于67Ga显像。在化疗过程中和化疗后持续18F-FDG PET阳性对预测复发有高灵敏度。治疗结束时18F-FDG PET阴性提示患者预后好。与其他常规显像相比,18F-FDG PET在监测淋巴瘤疗效、判断治疗反应方面有独特优势。
Abstract:
18F-FDG PET is an important imaging technique in the stage of patients with lymphoma and more sensitive and accurate than gallium scintigraphy. Persistently positive PET imaging during and after chemotherapy have a high sensitivity for predicting subsequent relapse. A negative PET imaging at the end of therapy provides favorable prognostic information. Compared to other conventional imaging modalities, 18F-FDG PET significantlyimproves the accuracy of imaging tumors in initial staging, and monitoring of therapy response of lymphoma.

参考文献/References:

1 Elstrom R,Guan L,Baker G,et al.Utility of FDG-PET scanning inlymphoma by WHO classification[J].Blood,2003,101(10):3875-3876.
2 Hoffmann M,Kletter K,Becherer A,et al.18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) for staging and follow-up of marginal zone B-cell lymphoma[J]. Oncology,2003,64(4):336-340.
3 Jerusalem G,Beguin Y,Najjar F,et al.Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin’s lymphoma (NHL)[J].Ann Oncol,2001,12(6):825-830.
4 Najjar F,Hustinx R,Jerusalem G,et al.Positron emission tomography (PET) for staging low-grade non-Hodgkin’s lymphomas (NHL)[J].Cancer Biother Radiopharm,2001,16(4):297-304.
5 Bangerter M,Moog F,Buchmann I,et al.Whole-body 2-[18F]-fluo-ro-2-deoxy-D-glucose positron emission tomography (FDG-PET)for accurate staging of Hodgkin’s disease[J].Ann Oncol,1998,9(10):1117-1122.
6 Wirth A,Seymour JF,Hicks RJ,et al.Fluorine-18 fluorodeoxyglu-cose positron emission tomography,gallium-67 scintigraphy,and conventional staging for Hodgkin’s disease and non-Hodgkin’s lym-phoma[J].Am J Med,2002,112(4):262-268.
7 Buchmann I,Reinhardt M,Elsner K,et al.2-(fluorine-18) fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma.A bicenter trial[J].Cancer,2001,91(5):889-899.
8 Moog F,Bangerter M,Kotzerke J,et al.18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lym-phomatous bone marrow[J].J Clin Oncol,1998,16:603-609.
9 Hueltenschmidt B,Sautter-Bihl ML,Lang O,et al.Whole body positron emission tomography in the treatment of Hodgkin disease[J].Cancer,2001,91(2):302-310.
10 Kostakoglu L,Goldsmith SJ. 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast,lung,and colorectal carcino-ma[J].J Nucl Med,2003,44(2):224-239.
11 Kostakoglu L,Coleman M,Leonard JP,et al.PET predicts prognosis after1 cycle of chemotherapy in aggressive lymphoma and Hodgkin’s disease[J].J Nucl Med,2002,43(8):1018-1027.
12 Jerusalem G,Beguin Y,Fassotte MF,et al.Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin’s disease and non-Hodgkin’s lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging[J].Blood,1999,94(2):429-433.
13 Spaepen K,Stroobants S,Dupont P,et al.Prognostic value of-positron emission tomography (PET) with fluorine-18 fluorodeoxyglu-cose ([18F]FDG)after first-line chemotherapy in non-Hodgkin’s lymphoma:is[18F]FDG-PET a valid alternative toconventional diagnostic methods?[J].J Clin Oncol,2001,19(2):414-419.
14 Becherer A,Mitterbauer M,Jaeger U,et al.Positron emission tomography with[18F]2-fluoro-D-2-deoxyglucose (FDG-PET)predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation[J].Leukemia,2002,16(2):260-267.
15 Spaepen K,Stroobants S,Dupont P,et al.Prognostic value of pretransplantation positron emission tomography using fluorine18-fluo-rodeoxyglucose in patients with aggressive lymphoma treated with-high-dose chemotherapy and stem cell transplantation[J].Blood,2003,102(1):53-59.

相似文献/References:

[1]岳进,苏丽萍.全身MRI与PET/CT在淋巴瘤骨髓浸润诊断及预后中的作用[J].国际放射医学核医学杂志,2016,40(1):50.[doi:10.3760/cma.j.issn.1673-4114.2016.01.010]
　Yue Jin,Su Lipin.Function of whole-body MRI and PET/CT in the diagnosis and prognosis of lymphoma with bone marrow infiltration[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):50.[doi:10.3760/cma.j.issn.1673-4114.2016.01.010]
[2]尤阳,轩昂,张杰,等.淋巴瘤患者大脑静息葡萄糖代谢改变[J].国际放射医学核医学杂志,2016,40(4):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
　You Yang,Xuan Ang,Zhang Jie,et al.Changes in resting-state brain glucose metabolism in patients with lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
[3]胡娜,吴永港,肖立志,等.18F-FDG PET/CT代谢活性参数及其在淋巴瘤中的应用[J].国际放射医学核医学杂志,2015,39(4):342.[doi:10.3760/cma.j.issn.1673-4114.2015.04.015]
　Hu Na,Wu Yonggang,Xiao Lizhi,et al.Metabolic parameters of 18F-FDG PET/CT and their application in lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):342.[doi:10.3760/cma.j.issn.1673-4114.2015.04.015]
[4]戴娜,吴翼伟.影像学技术在霍奇金淋巴瘤诊疗中的价值[J].国际放射医学核医学杂志,2014,38(2):117.[doi:10.3760/cma.j.issn.1673-4114.2014.02.011]
　Dai Na,Wu Yiwei.The value of medical imaging methods in diagnosis and treatment of Hodgkin lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(5):117.[doi:10.3760/cma.j.issn.1673-4114.2014.02.011]
[5]杨希,党春江.泌尿系统原发性结外淋巴瘤的临床及影像学表现[J].国际放射医学核医学杂志,2013,37(4):230.[doi:10.3760/cma.j.issn.1673-4114.2013.04.010]
　YANG Xi,DANG Chun-jiang.The clinical and imaging appearances of primary extranodal lymphoma of the urinary system[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(5):230.[doi:10.3760/cma.j.issn.1673-4114.2013.04.010]
[6]李艳梅,杨建伟,李鹏,等.单眼虹膜原发非霍奇金淋巴瘤18F-FDGPET/CT显像及疗效评价一例[J].国际放射医学核医学杂志,2013,37(5):326.[doi:10.3760/cma.j.issn.1673-4114.2013.05.017]
[7]萨日,赵红光,关锋,等.18F-FDG PET/CT在弥漫性大B细胞淋巴瘤疗效评价中的临床价值[J].国际放射医学核医学杂志,2013,37(1):9.[doi:10.3760/cma.j.issn.1673-4114.2013.01.003]
　SA Ri,ZHAO Hong-guang,GUAN Feng,et al.Clinical value of 18F-FDG PET/CT in evaluation of curative effect on diffuse large B cell lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(5):9.[doi:10.3760/cma.j.issn.1673-4114.2013.01.003]
[8]谢彦婷,郑容.18F-FDG PET/CT在食管癌放疗中的应用[J].国际放射医学核医学杂志,2013,37(1):42.[doi:10.3760/cma.j.issn.1673-4114.2013.01.012]
　XIE Yan-ting,ZHENG Rong.The application of 18F-FDG PET/CT in the radiotherapy of esophageal cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(5):42.[doi:10.3760/cma.j.issn.1673-4114.2013.01.012]
[9]王月英,吴红英,李德冠,等.小鼠不同肿瘤模型对放化疗敏感性的研究[J].国际放射医学核医学杂志,2012,36(5):289.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.006]
　WANG Yue-ying,WU Hong-ying,LI De-guan,et al.The radiation sensitivities of different mice tumor model to radiotherapy and chemotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(5):289.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.006]
[10]李倩,刘建军.18F-FDG PET-CT评价淋巴瘤疗效及预后的价值[J].国际放射医学核医学杂志,2011,35(4):220.[doi:10.3760/cma.j.issn.1673-4114.2011.04.006]
　LI Qian,LIU Jian-jun.The value of 18F-FDG PET-CT in lymphoma therapy evaluation and prognosis[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(5):220.[doi:10.3760/cma.j.issn.1673-4114.2011.04.006]

备注/Memo

备注/Memo:
收稿日期:2004-06-18。
更新日期/Last Update: 1900-01-01